International collaborative study to evaluate and calibrate two recombinant L chain Ferritin preparations for use as a WHO International Standard

Bernard Fox,Graham Roberts,Eleanor Atkinson,Peter Rigsby,Christina Ball
DOI: https://doi.org/10.1515/cclm-2021-1139
2021-12-17
Clinical Chemistry and Laboratory Medicine (CCLM)
Abstract:Abstract Objectives To evaluate and calibrate two candidate preparations for the 4th International Standard for Ferritin (Human, Recombinant) (codes: 19/118 and 19/162) against the 3rd International Standard for Ferritin (Human, Recombinant) (code: 94/572), and three serum commutability samples in an international collaborative study involving 12 laboratories in nine countries. Methods Eleven of the 12 participating laboratories performed Ferritin quantitation using automated assay platforms and one laboratory used a manual ELISA kit. Results There was better overall agreement between all laboratories and between assay methods for the potency of preparation 19/118 than for preparation 19/162. The overall geometric mean potency (from all methods) of the candidate 4th International Standard, 19/118, was 10.5 μg/ampoule, with inter-laboratory variability, expressed as % geometric coefficient of variation (GCV), of 4.7%. Accelerated stability studies have predicted both 19/118 and 19/162 to be very stable for long term storage at −20 °C. Conclusions The candidate 4th International Standard for Ferritin (Human, Recombinant) (19/118) has been shown to be immunologically similar to the 3rd International Standard for Ferritin (Human, Recombinant) (94/572). It was recommended to and accepted by the WHO Expert Committee on Biological Standardization that 19/118 be established as the 4th International Standard for Ferritin (Human, Recombinant) with an assigned potency of 10.5 μg/ampoule and expanded uncertainty limits 10.2–10.8 μg/ampoule (95% confidence; k =2.23).
What problem does this paper attempt to address?